Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA’s Revised Marketing Code: So Far, So What?

Executive Summary

The Pharmaceutical Research and Manufacturers of America's revised marketing code, which went into effect Jan. 1, seems to be going over with - a shrug. Yes, manufacturers are complying and doctors see some changes in long-standing promotion traditions. But the upshot for pharma seems to be, at least from the sales force perspective, so what

You may also be interested in...



Pharma's 2010 Promotional Budget: Fewer Reps But Same Dollars

Pharma's spending on product promotional activities in the United States has remained level over the past five years, even as companies continue with ambitious cost-cutting programs that have cut sales forces by more than 25%, according to the market research firm SDI.

Pharma's 2010 Promotional Budget: Fewer Reps But Same Dollars

Pharma's spending on product promotional activities in the United States has remained level over the past five years, even as companies continue with ambitious cost-cutting programs that have cut sales forces by more than 25%, according to the market research firm SDI.

Revised Sunshine Act Pre-empts State Reporting Duplications, Not Differences

Senate Finance Committee Investigative Counsel Christopher Armstrong said the goal of pre-emption provisions in the latest version of the Physician Payment Sunshine Act is to create neither a floor nor ceiling for state reporting requirements, but merely to prevent duplicate reporting on state and federal levels

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel